News and Announcements
Analytica Appoints New Board Director
- Published May 23, 2017 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Analytica Ltd (ASX: ALT) is pleased to announce the appointment of Dr. Peter B.Corr to the Board of Analytica Ltd. Dr. Corr has been invited to join the Board due to his extensive experience in the discovery and development of medicines in multiple indications, as well as the sale of assets to major multinational corporations.
KEY TAKEAWAYS:
- Dr. Corr was Professor, Department of Medicine (Cardiology) and Professor, Department of Pharmacology and Molecular Biology at Washington University in St. Louis.
- His research has been published in more than 160 scientific manuscripts.
- Dr. Corr, who received his doctorate from Georgetown University School of Medicine, spent 18 years as a researcher in molecular biology and pharmacology at Washington University in St. Louis.
- Dr. Corr was Professor, Department of Medicine (Cardiology) and Professor, Department of Pharmacology and Molecular Biology.
- Dr. Corr is the recipient of numerous awards, including membership in the Alpha Omega Alpha National Medical Honorary Society, an Established Investigator Award from the American Heart Association, and a Research Career Development Award from the National Institutes of Health.
He is a past Governor of the New York Academy of Sciences (and past Chairman of the Board of Governors) and a member of the Board of Regents of Georgetown University, and a past Member. He is currently Chairman of the Board of ADC Therapeutics, SA in Lausanne, Switzerland and a Board Member of Imvax, Inc. based in Philadelphia.
Dr. Corr is also the majority owner and director of INOV8, LLC in the US Virgin Islands which has a 12.58% shareholding in Analytica Ltd.
The Board has also offered to Dr Corr, subject to shareholder approval at the next shareholders meeting a grant of 10 million options with an exercise price of $0.013 and a 5 year life.
Analytica’s lead product is the PeriCoach® System – an e-health treatment system for women who suffer Stress Urinary Incontinence. This affects 1 in 3 women worldwide and is mostly caused by trauma to the pelvic floor muscles as a result of pregnancy, childbirth and menopause. PeriCoach comprises a device, web portal and smartphone app. The device evaluates activity in pelvic floor muscles. This information is transmitted to a smartphone app and can be loaded to a cloud database where physicians can monitor patient progress via web portal.
Company Updates
The Biofilm Breakthrough: How An Australian BioTech Firm Is Tapping Indonesia’s $45,000-a-Kitchen Bottleneck
Australian sustainability and deep-tech firm Altair International Pty Ltd is commercialising plant-based clinical hygiene technology, targeting a prime operational bottleneck in Indonesia’s massive national free meals program. Every few years, an Australian deep-tech company emerges combining proprietary science with a transformational anchor contract, the kind of business that quietly creates an entirely new market category […]
THE TAX CHANGED. NOW THE PRODUCT IS CHANGING TO MATCH.
Changes to the 50% capital gains tax discount are shifting Australian private capital away from growth and into high-yielding wrappers. Fund managers are actively redesigning products across private credit and property to capture the incoming capital rotation
The Algorithm Re-Dosing Cancer Treatment: Inside the University of Melbourne Spin-Out Rewriting a 60-Year-Old Formula
Oncology specialists are still calculating toxic chemotherapy doses using a formula from the era of the Ford Model T, leading to a system where seven out of eight patients are routinely overdosed. University of Melbourne spin-out PredicTx is dismantling this legacy approach, utilizing advanced AI to analyze existing patient CT scans, deliver precision medicine to the bedside, and return a massive 100x financial rerate to hospital networks.
Backed By Leading Investment Groups and Family Offices
